Biogen Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
6.9%projected annual EPS growth
Analyst Coverage
32analysts covering
FY Revenue (est.)
$10.4Bnext fiscal year
FY EPS (est.)
$12.45next fiscal year
Monitoring Framework
Key Performance Indicators
Leqembi Global In-Market Sales Quarterly121MTarget: Continued sequential demand growth and sales escalation through 2026-2027
Skyclarys Global Revenue Growth Annually30.0%Target: Geographic expansion into Latin America, Türkiye, and Middle East in 2026
Fit-for-Growth Operating Expense Savings Annually1BTarget: $100 billion gross and $800 million net savings in operating expenses%
Watch Items
- Multiple Sclerosis Franchise Revenue ErosionTrigger: Double-digit year-over-year declines in legacy MS products (e.g., Tecfidera, Tysabri)Action: Accelerate commercial execution of launch products (Leqembi, Skyclarys, Zurzuvae) to offset legacy declines
- Late-Stage Pipeline ReadoutsTrigger: Phase III clinical trial data turn-overs for 10 active programsAction: Prepare launch infrastructure, medical affairs, and commercialization strategies for positive readouts
Research as of 2 Sep 2026